İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025

Multicenter Retrospective Study of Stereotactic Radiosurgery for Gynecological Cancer Brain Metastases

Neurosurgery

YÖKSİS OpenAlex SJR Q1 JCR Q1 Atıf 4 Üst %10 Yüzdelik 90.8% FWCI 2.8
Yıl
2025
ISSN
0148-396X
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

BACKGROUND AND OBJECTIVES: Gynecological cancers represent 10% to 15% of cancers in women, but brain metastases (BM) are uncommon, with limited evidence regarding their management. This study investigates the role of stereotactic radiosurgery (SRS) for BM from primary gynecological cancers. METHODS: Institutions of the International Radiosurgery Research Foundation participated in this study. Inclusion criteria required histological diagnosis of epithelial ovarian, cervical, or endometrial cancer, SRS between 2000 and 2020, and at least 1 imaging or clinical follow-up. RESULTS: A total of 276 patients having SRS for 977 BM were included. Median age at SRS was 62 years (IQR, 55-70). Primary cancer origin was ovarian in 128 (46%), cervical in 43 (16%), and endometrial in 105 patients (38%). Median Karnofsky Performance Scale was 80%, and systemic disease was active in 124 (45%) of patients. A median of 1 metastasis was treated (IQR, 1-3) per patient. Median individual metastasis volume was 0.27 cc (IQR, 0.05-1.59 cc). The majority (91%) received single-fraction SRS, using a median margin dose of 18 Gy (IQR, 16-20 Gy). Actuarial overall survival was 77%, 65%, and 44% at 6, 12, and 24 months, respectively. Predictors of worsened survival included older age, cervical and endometrial primary, previous whole-brain radiation therapy (WBRT), active systemic disease, worsened Karnofsky Performance Scale, absence of subsequent surgery, and increasing number of BM. Actuarial local control was 94% at 6 months, 89% at 12 months, and 78% at 24 months. Previous SRS or WBRT, tumor bed treatment, and cervical histology increased the risk of local failure. New remote BM and leptomeningeal dissemination occurred in 44% and 11% of patients, respectively. Adverse radiation effects (ARE) occurred in 13% of cases but were symptomatic in only 3%. Previous WBRT or SRS and increased tumor diameter increased the risk of ARE. CONCLUSION: SRS is an effective management for BM from gynecological cancers with low risks of symptomatic ARE.

Konular

  • Brain Metastases and Treatment
  • Glioma Diagnosis and Treatment
  • Meningioma and schwannoma management

Birincil konu Brain Metastases and Treatment

Yazarlar

  1. MATHILDE BILLAU
  2. ANDREANNE HAMEL
  3. JEAN-NICOLAS TOURIGNY
  4. CHRISTIAN IORIO-MORIN
  5. ROMAN LISCAK
  6. JAROMIR MAY
  7. AJAY NIRANJAN
  8. ZHISHUO WEI
  9. L DADE LUNSFORD
  10. DIEGO D LUY
  11. SHALINI JOSE
  12. SYDNEY SCANLON
  13. JOSHUA SILVERMAN
  14. REED MULLEN
  15. KENNETH BERNSTEIN
  16. DOUGLAS KONDZIOLKA
  17. SELÇUK PEKER KOÇ ÜNİVERSİTESİ
  18. MUSTAFA YAVUZ SAMANCI İSTANBUL MEDİPOL ÜNİVERSİTESİ
  19. STEVE BRAUNSTEIN
  20. CHRISTINA PHUONG
  21. JASON SHEEHAN
  22. STYLIANOS PIKIS
  23. JACOB KOSYAKOVSKY
  24. RAHUL NEAL PRASAD
  25. JOSHUA DAVID PALMER
  26. DAVID BAILEY
  27. BRAD E. ZACHARIA
  28. CHRISTOPHER P CIFARELLI
  29. DENISSE ARTEAGA ICAZA
  30. DANIEL T CIFARELLI
  31. RODNEY E WEGNER
  32. MATTHEW J SHEPARD
  33. GREG N BOWDEN
  34. NARINE WANDREY
  35. CHAD G RUSTHOVEN
  36. ERIC B HINTZ
  37. MICHAEL SCHULDER
  38. ANUJ GOENKA
  39. JENNIFER L. PETERSON
  40. DAVID MATHIEU